Novo Nordisk receives approval in the US for PrandiMet(TM)
Novo Nordisk today announced that the US Food and Drug Administration
(FDA) has approved PrandiMet(TM), a fixed-dose combination of the
fast-acting insulin secretagogue repaglinide and metformin for the
treatment of type 2 diabetes.
PrandiMet(TM) has been approved as an adjunct to diet and exercise to
improve glycaemic control in adults with type 2 diabetes who are
already treated with a meglitinide (such as Prandin®) and metformin
or who have inadequate glycaemic control on a meglitinide alone or
metformin alone."As the world's leading diabetes care company, Novo Nordisk is
dedicated to providing a broad portfolio of treatments that respond
to each stage of diabetes. With PrandiMet(TM), physicians will have a
simplified option for Prandin® and metformin combination therapy,"
said Jerzy Gruhn, president, Novo Nordisk, Inc.
About PrandiMet(TM)
PrandiMet(TM) is indicated for the treatment of type 2 diabetes and
includes two approved products with well established data for safety
and efficacy: repaglinide (Prandin®) and metformin. It is the first
fixed-dose combination of repaglinide, a fast-acting insulin
secretagogue, and metformin, an insulin sensitiser. PrandiMet(TM)
combines two antihyperglycaemic agents with different mechanisms of
action in one tablet to improve glycaemic control. PrandiMet(TM)
works to control three abnormalities of type 2 diabetes: impaired
insulin secretion, insulin resistance and excessive hepatic glucose
production.
PrandiMet(TM) is available in two dosage strengths - 1mg
(repaglinide)/500mg (metformin) and 2mg (repaglinide)/500mg
(metformin), dosed 2-3 times per day with meals.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Contacts for further information:
Media: Investors:
Outside North America: Outside North America:
Mike Rulis Mads Veggerby Lausten
Tel: (+45) 4442 3573 Tel: (+45) 4443 7919
mike@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 39 / 2008